Recursion Pharmaceuticals vs Wave Life Sciences
Recursion Pharmaceuticals is the larger business, with $74.7m of revenue in fiscal 2025 against $42.7m for Wave Life Sciences (1.7 times as much). Recursion Pharmaceuticals grew faster (26.9% against -60.5%). Wave Life Sciences kept more of each dollar of sales as profit: a net margin of -478.3% against -863.4%.
| Latest fiscal year | Recursion PharmaceuticalsRXRX, 2025 | Wave Life SciencesWVE, 2025 |
|---|---|---|
| Revenue | $74.7m | $42.7m |
| Revenue growth | 26.9% | -60.5% |
| Net income | −$645m | −$204m |
| Operating margin | -867.9% | — |
| Net margin | -863.4% | -478.3% |
| Return on equity | -59.5% | -56.2% |
| Free cash flow | −$378m | −$188m |
| Cash | $743m | $602m |
| Total debt | $18.7m | $0 |
| Debt to equity | 1.6% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 317 |
| Market value | $2.10bn | $707m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 35 sales | 6 buys, 46 sales |